Human Papillomavirus (HPV)

Overview

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. Nearly 80% of sexually active people will be infected with at least one HPV type at some point in their lives — yet the vast majority of those people will never know it, because most infections are completely silent and go away on their own.

Scientists have identified over 200 distinct HPV types. The good news: more than 90% of HPV infections clear within one to two years because the immune system quietly eliminates the virus without any treatment needed. The infections that linger — particularly with certain "high-risk" types — are what can occasionally lead to cancer over the course of many years.

HPV types are broadly divided into two groups:

The Gardasil-9 vaccine is highly effective at preventing HPV infection and the cancers it can cause. It works best when given before a person becomes sexually active. Routine vaccination of adolescents is one of the most powerful cancer-prevention tools available today.

Epidemiology

HPV is extraordinarily common. The CDC estimates that approximately 43 million new HPV infections occurred in the United States in 2018 alone. Infection rates are highest in people in their late teens and early 20s, reflecting the onset of sexual activity. Both men and women are infected at roughly equal rates, though the disease burden (particularly cancer) falls more heavily on women.

Globally, HPV causes an estimated 690,000 cancers per year according to the International Agency for Research on Cancer (IARC) and the World Health Organization. Cervical cancer is the fourth most common cancer in women worldwide. The burden is especially severe in low- and middle-income countries, where cervical cancer screening programs are limited or unavailable, allowing treatable precancerous lesions to progress undetected to invasive cancer.

In the United States, widespread Pap smear screening has dramatically reduced cervical cancer deaths over the past 50 years. Since the introduction of HPV vaccines in 2006, rates of high-grade precancerous cervical lesions and genital warts in young women have fallen sharply in countries with high vaccine uptake.

Biology: Over 200 Types

HPV is a small, non-enveloped virus with a circular double-stranded DNA genome. More than 200 distinct types have been identified and classified based on their DNA sequence. Understanding how HPV types differ helps explain why some cause cancer while others merely cause warts.

High-Risk (Oncogenic) Types

At least 13 HPV types are classified as high-risk or oncogenic. The two most important are:

Low-Risk Types

HPV 6 and 11 are responsible for about 90% of genital warts (condylomata acuminata) and for a rare condition called recurrent respiratory papillomatosis (benign growths in the larynx and airways). These types do not cause cancer.

How HPV Causes Cancer

HPV infects the basal (deepest) layer of skin and mucosal cells, gaining entry through tiny abrasions during sexual contact. In most cases the immune system clears the infection within months to a couple of years. When a high-risk type persists, its viral proteins — particularly E6 and E7 — interfere with two critical cellular guard proteins:

With both brakes disabled, infected cells can accumulate DNA errors and divide uncontrollably over many years — a slow progression from normal cells to precancerous changes to, in some cases, invasive cancer. This process typically takes 10 to 20 years, which is exactly why regular screening is so effective at catching and treating precancerous changes long before cancer develops.

Clinical Manifestations

Most HPV infections produce no symptoms at all. When HPV does cause visible disease, the manifestation depends on the type involved.

Genital Warts (Condylomata Acuminata)

Caused by low-risk types HPV 6 and 11, genital warts appear as flesh-colored, soft, cauliflower-like growths on the genitals, perianal region, or inner thighs. They are not cancerous. Warts can appear weeks to months after infection and range from a single small bump to large clusters. They can be treated but not permanently cured by removal alone — the virus remains in surrounding tissue and warts often recur. Treatment options include:

Non-Genital Warts

Common warts (hands, fingers), plantar warts (feet), and flat warts are caused by cutaneous HPV types that do not infect the genital tract.

Recurrent Respiratory Papillomatosis (RRP)

A rare but serious condition in which HPV 6 or 11 causes benign papillomas (growths) in the larynx, vocal cords, and airways. It occurs in two forms: juvenile-onset (transmitted from mother to baby during delivery) and adult-onset. Management requires repeated surgical removal of papillomas to maintain an open airway; adjunct therapies such as cidofovir or bevacizumab are used in severe cases.

Precancerous Cervical Changes

High-risk HPV types can cause abnormal cervical cells detected on Pap smear or biopsy. These are graded by severity (CIN 1, 2, 3 — see Screening section). High-grade changes (HSIL/CIN2-3) are treated to prevent progression to cancer.

Cervical Cancer

Almost all cervical cancers (99%+) are caused by HPV, with HPV 16 and 18 responsible for the majority. Cervical cancer develops over a long period — typically 10 to 20 years from initial HPV infection to invasive cancer — which is why routine screening is so effective.

Other HPV-Related Cancers

Cervical Cancer Screening

Cervical cancer screening is one of modern medicine's great success stories. Because cancer develops slowly over many years from detectable precancerous changes, regular screening catches the process early — when it is easily treatable. All women with a cervix should follow screening guidelines regardless of HPV vaccination status.

Screening Tests

Current Guidelines (USPSTF / ASCCP 2018–2019)

Understanding Abnormal Results

Abnormal Pap or positive HPV results lead to further evaluation, most often with colposcopy — a magnified examination of the cervix — and biopsy if needed. Biopsies are graded using the CIN system:

The most common treatment for CIN 2–3 is LEEP (loop electrosurgical excision procedure), which removes the abnormal tissue with a thin wire loop. It is highly effective and usually done as an outpatient procedure.

Gardasil-9 Vaccine

Vaccination is the most powerful tool available for HPV prevention. The Gardasil-9 (9vHPV) vaccine protects against nine HPV types: the two that cause most genital warts (6 and 11) and seven high-risk types that cause most HPV-related cancers (16, 18, 31, 33, 45, 52, and 58). Together, these nine types account for approximately 90% of all HPV-related cancers and nearly all genital warts.

Who Should Get Vaccinated

Dosing Schedule

How Effective Is It?

In clinical trials, Gardasil-9 was over 90–95% effective at preventing infection with the HPV types it covers when given to people before exposure. In per-protocol analyses (people who received all doses and had no prior HPV exposure), the vaccine showed near-100% efficacy against CIN 2/3 (precancerous cervical lesions) and genital warts caused by vaccine types.

Safety

Gardasil-9 has an excellent safety record. Post-marketing surveillance has now covered more than 270 million doses delivered worldwide. The most common side effects are mild: pain, redness, or swelling at the injection site. Syncope (fainting) can occur shortly after any injection — clinics ask patients to sit for 15 minutes afterward as a precaution. Large-scale studies have found no increased risk of serious adverse events compared to control groups.

Why Vaccinating Boys and Men Matters

HPV vaccination is gender-neutral — males benefit directly (prevention of genital warts, anal and oropharyngeal cancers, and penile cancer) and indirectly (reducing transmission to partners). Vaccinating both sexes maximizes herd immunity and has the greatest population-level impact on reducing HPV-related cancers.

Oropharyngeal and Anal HPV

While cervical cancer is the best-known HPV-related malignancy, two other cancer sites deserve attention because their rates are rising — often in people who are unaware of their risk.

Oropharyngeal Cancer

HPV 16 is now the most common cause of oropharyngeal squamous cell carcinoma (OPSCC) in the United States — cancers of the base of the tongue, tonsils, and soft palate. This represents a dramatic epidemiological shift: while tobacco-related head and neck cancers have been declining, HPV-related OPSCC rates have risen sharply over the past 30 years, particularly in middle-aged men. HPV-positive oropharyngeal cancers tend to respond better to treatment and have a better prognosis than tobacco-related head and neck cancers, though they are still serious diagnoses requiring intensive therapy.

There is currently no approved screening program for oropharyngeal HPV (unlike cervical cancer). Early symptoms — persistent sore throat, difficulty swallowing, a lump in the neck, or ear pain — should prompt medical evaluation.

Anal Cancer

Anal cancer rates have been rising steadily, with the sharpest increases in HIV-positive men who have sex with men (MSM), among whom anal HPV infection is highly prevalent. HPV 16 accounts for the majority of anal cancers. An anal Pap smear (anal cytology) and HPV testing are increasingly used in high-risk populations (MSM and people living with HIV) to detect precancerous anal changes, though no universally accepted screening guideline has been established. Referral for high-resolution anoscopy is used when abnormalities are detected.

Natural History and Clearance

Perhaps the most reassuring fact about HPV is how effectively the immune system deals with it. Approximately 90% of HPV infections clear within 1–2 years through the normal workings of the immune system. Many people will never know they were infected. The body generates robust T-cell and antibody responses against the virus, and for most people this is more than sufficient to eliminate it completely.

It is persistent infection — when a high-risk HPV type is still detectable after two or more years — that carries cancer risk. Even then, progression to invasive cancer is not inevitable and typically takes another decade or more. This slow timeline is precisely why cervical screening programs are so effective: there is a long window during which precancerous changes can be detected and treated before cancer ever develops.

Risk Factors for Persistence

Diagnosis and Testing

HPV diagnosis works quite differently from most other infections because the virus cannot be cultured in a standard laboratory and there is no useful blood test to detect it.

Treatment of HPV-related Conditions

There is currently no antiviral medication that eliminates HPV itself from the body. Treatment focuses on managing the conditions that HPV causes — warts, precancerous changes, and cancers.

Genital Warts

Precancerous Cervical Lesions (HSIL / CIN 2–3)

Cervical Cancer

Invasive cervical cancer is treated with standard oncologic approaches: surgery (hysterectomy ± lymph node dissection for early-stage disease), radiation therapy (often with concurrent chemotherapy — cisplatin-based chemoradiation for locally advanced disease), and immunotherapy (pembrolizumab has been FDA-approved for recurrent/metastatic cervical cancer with PD-L1 expression).

RRP (Recurrent Respiratory Papillomatosis)

Repeated surgical removal (microlaryngoscopy with microdebrider or laser) is the primary approach. Adjunct therapies including intralesional cidofovir injections and anti-VEGF therapy (bevacizumab) are used in severe cases to slow regrowth. There is no cure; management is lifelong for severe cases.

Key Research Papers

  1. Garland SM et al. (2007) — Quadrivalent HPV vaccine efficacy in women (FUTURE I trial). N Engl J Med 356:1928–43. PMID: 17494926
  2. FUTURE II Study Group (2007) — Quadrivalent HPV vaccine to prevent high-grade cervical lesions. N Engl J Med 356:1915–27. PMID: 17494925
  3. Arbyn M et al. (2018) — Prophylactic vaccination against HPV to prevent cervical cancer and its precursors (Cochrane). Lancet Oncol. PMID: 29494205
  4. Chesson HW et al. (2021) — HPV-attributable cancers — United States, 2012–2016. MMWR. PMID: 33760416
  5. Meites E et al. (2016) — Use of a 2-dose schedule for HPV vaccination — Updated recommendations. MMWR. PMID: 27820947
  6. Giuliano AR et al. (2015) — HPV infection and immunity: Review of natural history. J Infect Dis. PMID: 25651816
  7. PubMed: HPV cervical cancer screening and ASCCP guidelines
  8. PubMed: HPV oropharyngeal cancer incidence and epidemiology
  9. PubMed: HPV anal cancer HIV MSM screening
  10. PubMed: HPV immune clearance and persistence natural history
  11. PubMed: Gardasil-9 (9vHPV) vaccine efficacy and safety
  12. PubMed: HPV E6 E7 p53 Rb carcinogenesis mechanism

PubMed Research

  1. HPV epidemiology and prevalence in the United States
  2. HPV vaccine adolescent immunogenicity
  3. HPV cervical cancer LEEP treatment outcomes
  4. HPV genital warts treatment and recurrence
  5. HPV oropharyngeal squamous cell carcinoma prognosis
  6. HPV cervical intraepithelial neoplasia CIN regression
  7. HPV smoking risk factor cervical cancer
  8. HPV immunosuppression HIV cancer risk
  9. Recurrent respiratory papillomatosis HPV treatment
  10. HPV anal cytology and high-resolution anoscopy
  11. HPV vaccination herd immunity population effect
  12. HPV in low- and middle-income countries cervical cancer burden

Connections

Back to Table of Contents